Lytix Biopharma AS (DE:6BG) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lytix Biopharma, a Norwegian company focused on cancer treatment, is poised to benefit from its licensing agreement with Verrica Pharmaceuticals, which is working on advancing LTX-35 in cancer treatment. With Dr. Jayson Rieger now leading Verrica and also serving on Lytix’s board, the collaboration could enhance Lytix’s financial prospects, including potential milestone payments and royalties.
For further insights into DE:6BG stock, check out TipRanks’ Stock Analysis page.